Patent intelligence · US
US 11951100
Formulations of RBP4 inhibitors and methods of use
Formulations of RBP4 inhibitors and methods of use
Patent details — US 11951100
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 9, 2024
- Expiration
- Apr 4, 2044
- Applicant
- Belite Bio, Inc
- Claims
- 20
- CPC classes
- A61K, A61K31/437, A61K31/4545, A61K9/10
Quick answer
US 11951100 (Formulations of RBP4 inhibitors and methods of use) is held by Belite Bio, Inc. Status: granted. Granted Apr 9, 2024. Expires Apr 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Belite Bio, Inc
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/437, A61K31/4545, A61K9/10, A61K9/146, A61K9/1635
More from Belite Bio, Inc
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
granted -
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 11951100?
US 11951100 (Formulations of RBP4 inhibitors and methods of use) is held by Belite Bio, Inc. Status: granted. Granted Apr 9, 2024. Expires Apr 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11951100?
Belite Bio, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 11951100 expire?
Our index shows an expiration date of Apr 4, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.